Journal of Cancer Metastasis and Treatment,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 21, 2025
Gastric
cancer
remains
a
significant
global
health
burden,
and
while
immunotherapy
offers
promising
therapeutic
avenues,
its
efficacy
varies
greatly
among
patients.
The
key
challenge
is
accurately
identifying
treatment
responders,
alternative
strategies
are
necessary
for
non-responders.
Biomarkers
such
as
PD-L1
expression,
tumor
mutational
mismatch
repair
status,
Epstein-Barr
virus
infection
have
shown
predictive
potential,
yet
the
quest
more
reliable
markers
continues
to
be
challenging.
Emerging
technologies,
including
liquid
biopsy,
single-cell
sequencing,
artificial
intelligence,
present
novel
approaches
enhancing
individualized
research
improving
capabilities.
This
review
provides
comprehensive
analysis
of
current
biomarkers
introduces
emerging
candidates
from
recent
studies,
thereby
contributing
ongoing
efforts
refine
patient
stratification
strategies.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(2), P. 286 - 286
Published: Jan. 9, 2024
Despite
advances
in
treatment
strategies
and
surgical
approaches
recent
years,
improving
survival
outcomes
esophagogastric
cancer
(EGC)
patients
treated
with
curative
intent
remains
a
significant
area
of
unmet
need.
The
emergence
adjuvant
immunotherapy
as
the
standard
care
for
resected
EGC
demonstrates
impact
recurrence-free
survival.
Neoadjuvant
perioperative
immunotherapies
represent
another
promising
approach
potential
advantages
over
therapy.
results
early
neoadjuvant
studies,
there
are
several
challenges
future
research
needs.
optimal
timing,
duration
number
doses
relation
to
surgery
combination
still
unclear.
In
addition,
rigorous
correlative
studies
need
be
performed
identify
biomarkers
patient
selection
response
prediction
maximize
benefits
immunotherapy.
this
review,
we
provide
concise
summary
current
resectable
discuss
rationale
use
immune
checkpoint
inhibitors
setting
pre-clinical
clinical
data
these
novel
therapies.
Finally,
will
examine
role
direction
paradigm
perceived
opportunities
that
lay
ahead.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: May 9, 2024
Gastric/gastroesophageal
junction
(G/GEJ)
cancer
represents
a
significant
global
health
challenge.
Radical
surgery
remains
the
cornerstone
of
treatment
for
resectable
G/GEJ
cancer.
Supported
by
robust
evidence
from
multiple
clinical
studies,
therapeutic
approaches,
including
adjuvant
chemotherapy
or
chemoradiation,
and
perioperative
chemotherapy,
are
generally
recommended
to
reduce
risk
recurrence
enhance
long-term
survival
outcomes
post-surgery.
In
recent
years,
immune
checkpoint
inhibitors
(ICIs)
have
altered
landscape
systemic
advanced
metastatic
cancer,
becoming
standard
first-line
therapy
specific
patients.
Consequently,
exploring
efficacy
ICIs
in
neoadjuvant
setting
is
worthwhile.
This
review
summarizes
current
advances
application
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 14, 2025
In
the
realm
of
oncology,
tumor
microenvironment
(TME)—comprising
extracellular
matrix
components,
immune
cells,
fibroblasts,
and
endothelial
cells—plays
a
pivotal
role
in
tumorigenesis,
progression,
response
to
therapeutic
interventions.
Initially,
TME
exhibits
tumor-suppressive
properties
that
can
inhibit
malignant
transformation.
However,
as
progresses,
various
factors
induce
tolerance,
resulting
behaving
state
promotes
growth
metastasis
later
stages.
This
immunosuppression
is
crucial
it
enables
change
from
killing
cells
promoting
progression.
Gastric
cancer
common
gastrointestinal
tract
with
an
alarmingly
high
mortality
rate.
While
chemotherapy
has
historically
been
cornerstone
treatment,
its
efficacy
prolonging
survival
remains
limited.
The
emergence
immunotherapy
opened
new
pathways,
yet
challenge
tolerance
driven
by
gastric
complicates
these
efforts.
review
aims
elucidate
intricate
mediating
spotlight
innovative
strategies
clinical
trials
designed
enhance
immunotherapeutic
approaches.
By
providing
comprehensive
theoretical
framework,
this
seeks
advance
understanding
application
treatment
cancer,
ultimately
contributing
improved
patient
outcomes.
Journal of Cancer Metastasis and Treatment,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 21, 2025
Gastric
cancer
remains
a
significant
global
health
burden,
and
while
immunotherapy
offers
promising
therapeutic
avenues,
its
efficacy
varies
greatly
among
patients.
The
key
challenge
is
accurately
identifying
treatment
responders,
alternative
strategies
are
necessary
for
non-responders.
Biomarkers
such
as
PD-L1
expression,
tumor
mutational
mismatch
repair
status,
Epstein-Barr
virus
infection
have
shown
predictive
potential,
yet
the
quest
more
reliable
markers
continues
to
be
challenging.
Emerging
technologies,
including
liquid
biopsy,
single-cell
sequencing,
artificial
intelligence,
present
novel
approaches
enhancing
individualized
research
improving
capabilities.
This
review
provides
comprehensive
analysis
of
current
biomarkers
introduces
emerging
candidates
from
recent
studies,
thereby
contributing
ongoing
efforts
refine
patient
stratification
strategies.
